These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37190284)

  • 21. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
    Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
    Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.
    Park HY; Chae MK; Ko J; Kikkawa DO; Jang SY; Yoon JS
    PLoS One; 2022; 17(12):e0279060. PubMed ID: 36521376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.
    Ren L; Campbell A; Fang H; Gautam S; Elavazhagan S; Fatehchand K; Mehta P; Stiff A; Reader BF; Mo X; Byrd JC; Carson WE; Butchar JP; Tridandapani S
    J Biol Chem; 2016 Feb; 291(6):3043-52. PubMed ID: 26627823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,
    Chu Y; Lee S; Shah T; Yin C; Barth M; Miles RR; Ayello J; Morris E; Harrison L; Van de Ven C; Galardy P; Goldman SC; Lim MS; Hermiston M; McAllister-Lucas LM; Giulino-Roth L; Perkins SL; Cairo MS
    Oncoimmunology; 2019; 8(1):e1512455. PubMed ID: 30546948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ibrutinib.
    Charalambous A; Schwarzbich MA; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():133-168. PubMed ID: 30069629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.
    Muqbil I; Chaker M; Aboukameel A; Mohammad RM; Azmi AS; Ramchandren R
    Heliyon; 2019 Aug; 5(8):e02290. PubMed ID: 31508518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor efficacy of
    Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BTK Inhibition Reverses MDSC-Mediated Immunosuppression and Enhances Response to Anti-PDL1 Therapy in Neuroblastoma.
    Ishfaq M; Pham T; Beaman C; Tamayo P; Yu AL; Joshi S
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33669187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma.
    Lin CH; Elkholy KH; Wani NA; Li D; Hu P; Barajas JM; Yu L; Zhang X; Jacob ST; Khan WN; Bai XF; Noonan AM; Ghoshal K
    Mol Cancer Ther; 2020 Feb; 19(2):384-396. PubMed ID: 31582534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.
    Campbell R; Chong G; Hawkes EA
    J Clin Med; 2018 Mar; 7(4):. PubMed ID: 29561760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Btk with ibrutinib inhibit gastric carcinoma cells growth.
    Wang JD; Chen XY; Ji KW; Tao F
    Am J Transl Res; 2016; 8(7):3003-12. PubMed ID: 27508020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression Modulation of Immune Checkpoint Molecules by Ibrutinib and Everolimus Through STAT3 in MCF-7 Breast Cancer Cells.
    Soltanshahi M; Taghiloo S; Asgarian-Omran H
    Iran J Pharm Res; 2022 Dec; 21(1):e127352. PubMed ID: 35873012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
    Wei L; Su YK; Lin CM; Chao TY; Huang SP; Huynh TT; Jan HJ; Whang-Peng J; Chiou JF; Wu AT; Hsiao M
    Oncotarget; 2016 Oct; 7(43):69961-69975. PubMed ID: 27564106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
    Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
    O'Riordan CE; Purvis GSD; Collotta D; Chiazza F; Wissuwa B; Al Zoubi S; Stiehler L; Martin L; Coldewey SM; Collino M; Thiemermann C
    Front Immunol; 2019; 10():2129. PubMed ID: 31552054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
    Kondo K; Shaim H; Thompson PA; Burger JA; Keating M; Estrov Z; Harris D; Kim E; Ferrajoli A; Daher M; Basar R; Muftuoglu M; Imahashi N; Alsuliman A; Sobieski C; Gokdemir E; Wierda W; Jain N; Liu E; Shpall EJ; Rezvani K
    Leukemia; 2018 Apr; 32(4):960-970. PubMed ID: 28972595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
    Pan Y; Chiu YH; Chiu SC; Cho DY; Lee LM; Wen YC; Whang-Peng J; Hsiao CH; Shih PH
    Anticancer Res; 2020 Nov; 40(11):6093-6099. PubMed ID: 33109547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
    Cinar M; Hamedani F; Mo Z; Cinar B; Amin HM; Alkan S
    Leuk Res; 2013 Oct; 37(10):1271-7. PubMed ID: 23962569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.